COMMUNIQUÉ DE PRESSE publié le 14/11/2024 à 14:30, il y a 1 année 7 mois IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28% Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRÈVE publiée le 06/11/2024 à 14:35, il y a 1 année 7 mois IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRÈVE publiée le 06/11/2024 à 14:35, il y a 1 année 7 mois IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
COMMUNIQUÉ DE PRESSE publié le 06/11/2024 à 14:30, il y a 1 année 7 mois IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRÈVE publiée le 17/10/2024 à 14:35, il y a 1 année 8 mois IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRÈVE publiée le 17/10/2024 à 14:35, il y a 1 année 8 mois IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
COMMUNIQUÉ DE PRESSE publié le 17/10/2024 à 14:30, il y a 1 année 8 mois IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRÈVE publiée le 03/10/2024 à 15:05, il y a 1 année 8 mois IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRÈVE publiée le 03/10/2024 à 15:05, il y a 1 année 8 mois IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
COMMUNIQUÉ DE PRESSE publié le 03/10/2024 à 15:00, il y a 1 année 8 mois IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge
Publié le 26/06/2026 à 17:45, il y a 16 heures 34 minutes Descriptif du programme de rachat d'actions
Publié le 27/06/2026 à 01:40, il y a 8 heures 39 minutes Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Publié le 27/06/2026 à 00:00, il y a 10 heures 19 minutes Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Publié le 26/06/2026 à 23:00, il y a 11 heures 19 minutes Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Publié le 26/06/2026 à 22:50, il y a 11 heures 29 minutes Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Publié le 26/06/2026 à 22:15, il y a 12 heures 4 minutes Revive Therapeutics Announces Proposed Private Placement
Publié le 27/06/2026 à 00:05, il y a 10 heures 13 minutes EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Publié le 27/06/2026 à 00:04, il y a 10 heures 14 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 10 heures 43 minutes Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Publié le 26/06/2026 à 23:36, il y a 10 heures 43 minutes EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Publié le 26/06/2026 à 23:27, il y a 10 heures 51 minutes EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE